An open-label, randomized, single dose, crossover study to assess the pharmacokinetics, pharmacodynamics, safety, and tolerability of modified release formulations of GSK89075 [remogliflozin etabonate] in healthy volunteers.
Phase of Trial: Phase I
Latest Information Update: 01 Jun 2012
At a glance
- Drugs Remogliflozin etabonate (Primary)
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 12 Oct 2008 Status changed from active, no longer recruiting to completed.
- 18 Jan 2008 Status changed from initiated to in progress, in accordance with clinicaltrials.gov.
- 28 Nov 2007 New trial record.